According to fund sponsor T. Rowe Price, managers invest in four main categories: Pharmaceuticals, health care companies, ...
Zacks Investment Research on MSN
Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a strong ETF right now?
Designed to provide broad exposure to the Health Care ETFs category of the market, the State Street SPDR S&P Pharmaceuticals ...
Zacks Investment Research on MSN
Should you invest in the VanEck pharmaceutical ETF (PPH)?
Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launched on ...
The VanEck Pharmaceutical ETF (NYSEARCA:PPH) has surged 26% over the past year, driven almost entirely by the weight-loss ...
UNH earnings reveal rising margin pressure from Medicare Advantage; investors may look to these healthcare ETFs for ...
The VanEck Pharmaceutical exchange-traded fund is on a strong run this week as news of Pfizer's deal with the Trump administration helped boost pharmaceutical stocks. The ETF was up 1.1% at $94.36 in ...
Triple-leveraged ETFs aren’t for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull ...
Shares Biotechnology ETF (IBB) is a BUY: large-cap biotech stability, M&A and AI catalysts, and 2026 upside. Read the full analysis here.
A smart beta exchange traded fund, the State Street SPDR S&P Pharmaceuticals ETF (XPH) debuted on 06/19/2006, and offers broad exposure to the Health Care ETFs category of the market. What Are Smart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results